


## Tedalinab

<b>Cat. No.:</b>	HY-14900		
<b>CAS No.:</b>	916591-01-0		
<b>Molecular Formula:</b>	C <sub>19</sub> H <sub>21</sub> F <sub>2</sub> N <sub>3</sub> O		
<b>Molecular Weight:</b>	345.39		
<b>Target:</b>	Cannabinoid Receptor		
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling		
<b>Storage:</b>	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (289.53 mM; ultrasonic and warming and heat to 60°C)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.8953 mL	14.4764 mL	28.9528 mL
5 mM	0.5791 mL	2.8953 mL	5.7906 mL
10 mM	0.2895 mL	1.4476 mL	2.8953 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Tedalinab (GRC-10693) is a potent, orally active, and selective cannabinoid receptor 2 (CB2) agonist. Tedalinab has >4700-fold functional selectivity for CB2 over CB1. Tedalinab has potential for neuropathic pain and osteoarthritis treatment<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

CB2

### REFERENCES

[1]. Glenmark's molecule for neuropathic pain, osteoarthritis - GRC 10693, successfully completes Phase I trials.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA